Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer
© 2024. The Author(s), under exclusive licence to Springer Nature Limited..
BACKGROUND: Immune-related adverse events (irAEs) have been found to predict PD-L1 inhibitor efficacy in metastatic NSCLC. However, the relation of irAEs to clinical outcome for nonmetastatic NSCLC has remained unknown.
METHODS: In this multicenter prospective study of Stage III NSCLC treated with PACIFIC regimen, the relation of irAEs to PFS was evaluated by 8-week landmark analysis to minimise lead-time bias as well as by multivariable analysis adjusted for baseline factors. irAEs were categorised as mild or nonmild according to whether they were treated with systemic steroid.
RESULTS: Median PFS was 16.0 months, not reached, and 9.7 months for patients without (85 cases) or with mild (21 cases) or nonmild (21 cases) irAEs, respectively. Multivariable analysis indicated that nonmild irAEs were associated with poor PFS, with HRs of 3.86 (95% CI, 1.31-11.38) compared with no irAEs and 11.58 (95% CI, 2.11-63.63) compared with mild irAEs. This pattern was consistent after irAE grade, the number of durvalumab doses and immune profiles (PD-L1 score, CD8+ tumour-infiltrating lymphocyte density, and tumour mutation burden) were taken into consideration.
CONCLUSIONS: The development of mild irAEs might predict a better survival outcome, whereas immunosuppressive steroid-treated irAEs were associated with a worse outcome, regardless of baseline clinical and immune profiles.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
---|---|
Enthalten in: |
British journal of cancer - (2024) vom: 22. März |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Haratani, Koji [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Revised 23.03.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1038/s41416-024-02662-2 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370092775 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM370092775 | ||
003 | DE-627 | ||
005 | 20240324235305.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240324s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1038/s41416-024-02662-2 |2 doi | |
028 | 5 | 2 | |a pubmed24n1345.xml |
035 | |a (DE-627)NLM370092775 | ||
035 | |a (NLM)38519705 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Haratani, Koji |e verfasserin |4 aut | |
245 | 1 | 0 | |a Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 23.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a © 2024. The Author(s), under exclusive licence to Springer Nature Limited. | ||
520 | |a BACKGROUND: Immune-related adverse events (irAEs) have been found to predict PD-L1 inhibitor efficacy in metastatic NSCLC. However, the relation of irAEs to clinical outcome for nonmetastatic NSCLC has remained unknown | ||
520 | |a METHODS: In this multicenter prospective study of Stage III NSCLC treated with PACIFIC regimen, the relation of irAEs to PFS was evaluated by 8-week landmark analysis to minimise lead-time bias as well as by multivariable analysis adjusted for baseline factors. irAEs were categorised as mild or nonmild according to whether they were treated with systemic steroid | ||
520 | |a RESULTS: Median PFS was 16.0 months, not reached, and 9.7 months for patients without (85 cases) or with mild (21 cases) or nonmild (21 cases) irAEs, respectively. Multivariable analysis indicated that nonmild irAEs were associated with poor PFS, with HRs of 3.86 (95% CI, 1.31-11.38) compared with no irAEs and 11.58 (95% CI, 2.11-63.63) compared with mild irAEs. This pattern was consistent after irAE grade, the number of durvalumab doses and immune profiles (PD-L1 score, CD8+ tumour-infiltrating lymphocyte density, and tumour mutation burden) were taken into consideration | ||
520 | |a CONCLUSIONS: The development of mild irAEs might predict a better survival outcome, whereas immunosuppressive steroid-treated irAEs were associated with a worse outcome, regardless of baseline clinical and immune profiles | ||
650 | 4 | |a Journal Article | |
700 | 1 | |a Nakamura, Atsushi |e verfasserin |4 aut | |
700 | 1 | |a Mamesaya, Nobuaki |e verfasserin |4 aut | |
700 | 1 | |a Sawa, Kenji |e verfasserin |4 aut | |
700 | 1 | |a Shiraishi, Yoshimasa |e verfasserin |4 aut | |
700 | 1 | |a Saito, Ryota |e verfasserin |4 aut | |
700 | 1 | |a Tanizaki, Junko |e verfasserin |4 aut | |
700 | 1 | |a Tamura, Yosuke |e verfasserin |4 aut | |
700 | 1 | |a Hata, Akito |e verfasserin |4 aut | |
700 | 1 | |a Tsuruno, Kosuke |e verfasserin |4 aut | |
700 | 1 | |a Sakamoto, Tomohiro |e verfasserin |4 aut | |
700 | 1 | |a Teraoka, Shunsuke |e verfasserin |4 aut | |
700 | 1 | |a Oki, Masahide |e verfasserin |4 aut | |
700 | 1 | |a Watanabe, Hiroshi |e verfasserin |4 aut | |
700 | 1 | |a Tokito, Takaaki |e verfasserin |4 aut | |
700 | 1 | |a Nagata, Kenji |e verfasserin |4 aut | |
700 | 1 | |a Masuda, Takeshi |e verfasserin |4 aut | |
700 | 1 | |a Nakamura, Yasushi |e verfasserin |4 aut | |
700 | 1 | |a Sakai, Kazuko |e verfasserin |4 aut | |
700 | 1 | |a Chiba, Yasutaka |e verfasserin |4 aut | |
700 | 1 | |a Ito, Akihiko |e verfasserin |4 aut | |
700 | 1 | |a Nishio, Kazuto |e verfasserin |4 aut | |
700 | 1 | |a Yamamoto, Nobuyuki |e verfasserin |4 aut | |
700 | 1 | |a Nakagawa, Kazuhiko |e verfasserin |4 aut | |
700 | 1 | |a Hayashi, Hidetoshi |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d 1947 |g (2024) vom: 22. März |w (DE-627)NLM000027537 |x 1532-1827 |7 nnns |
773 | 1 | 8 | |g year:2024 |g day:22 |g month:03 |
856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41416-024-02662-2 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |j 2024 |b 22 |c 03 |